[
  {
    "categoryName": "Medicines",
    "groups": [
      {
        "group": "CAR-T",
        "items": [
          {
            "item": "Kymriah",
            "description": "First CAR-T approved in U.S.",
            "details": {
              "Maker": "Novartis",
              "Notes": "Approved in 2017. Initially approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Later it also got approved for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy."
            }
          },
          {
            "item": "Yescarta",
            "description": "Second CAR-T approved in U.S.",
            "details": {
              "Maker": "Gilead Sciences",
              "Notes": "Approved in 2017. It is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy."
            }
          }
        ]
      },
      {
        "group": "RSV vaccines",
        "items": [
          {
            "item": "Abrysvo",
            "description": "FDA considering for adults and maternal use in 2023.",
            "details": {
              "Maker": "Pfizer",
              "Notes": "Advisers voted 14-0 and 10-4 (safety for infant use and a closer 7-4 for older adults use in separate 2023 votes, approvals due August and May, respectively."
            }
          },
          {
            "item": "Arexvy",
            "description": "First RSV vaccine to win U.S. approval, in May 2023.",
            "details": {
              "Maker": "GSK",
              "Notes": "Cleared only for use in adults 60 years or older."
            }
          }
        ]
      }
    ]
  },
  {
    "categoryName": "Companies",
    "groups": [
      {
        "group": "Pfizer",
        "items": [
          {
            "item": "Covid vaccine",
            "description": "First CAR-T approved in U.S.",
            "details": {
              "Maker": "Novartis",
              "Notes": "Approved in 2017. Initially approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Later it also got approved for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy."
            }
          },
          {
            "item": "RSV vaccine",
            "description": "Second CAR-T approved in U.S.",
            "details": {
              "Maker": "Gilead Sciences",
              "Notes": "Approved in 2017. It is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy."
            }
          }
        ]
      }
    ]
  }
]
